ITCIUnknown

Intra-Cellular Therapies, Inc. Insider Trading Activity

Every SEC Form 4 insider transaction reported for Intra-Cellular Therapies, Inc. (ITCI), sourced directly from SEC EDGAR and updated as new filings are accepted.

Last updated:

Quick Answer

Are ITCI insiders buying or selling?

Intra-Cellular Therapies, Inc. insiders reported 7 open-market buys ($11.5M) and 132 sells ($200.6M) across 139 Form 4 filings — a net selling position of $189.1M.

Source: SEC EDGAR Form 4

Key Statistics (as of Dec 6, 2024)

Total Form 4 filings
139
SEC EDGAR
Insider filers
13
Insider buys (7)
$11.5M
Insider sells (132)
$200.6M

Insider sentiment

Net selling

Net insider flow of $189.1M in net selling.

Recent ITCI insider transactions

DateInsiderRoleTypeSharesPriceValue
Dec 6, 2024Sharon MatesChairman and CEOSale102.7K$84.93$8.7M
Nov 14, 2024Michael HalsteadPresidentSale41.6K$88.79$3.7M
Aug 30, 2024Sharon MatesChairman and CEOSale70.0K$72.70$5.1M
Aug 28, 2024Sharon MatesChairman and CEOSale95.9K$73.54$7.1M
Aug 23, 2024Sharon MatesChairman and CEOSale121.1K$75.05$9.1M
Aug 20, 2024Mark NeumannEVP, Chief Commercial OfficerSale18.7K$75.08$1.4M
Jun 25, 2024RIGGS RORY BDirectorSale4.5K$75.57$337.2K
Jun 21, 2024Nostrand Robert L VanDirectorSale20.0K$75.91$1.5M
Mar 12, 2024Sharon MatesChairman, President & CEOSale61.3K$66.07$4.0M
Mar 12, 2024Lawrence J. HinelineSVP of Finance, CFOSale23.3K$66.32$1.5M
Mar 12, 2024Michael HalsteadEVP and General CounselSale20.5K$66.09$1.4M
Mar 12, 2024Mark NeumannEVP, Chief Commercial OfficerSale20.5K$66.23$1.4M
Mar 12, 2024Suresh K. DurgamEVP, Chief Medical OfficerSale10.2K$66.21$672.8K
Feb 29, 2024Nostrand Robert L VanDirectorSale20.0K$72.93$1.5M
Feb 28, 2024Michael HalsteadEVP and General CounselSale7.9K$69.53$549.8K
Feb 28, 2024Lawrence J. HinelineSVP of Finance, CFOSale13.3K$69.43$926.0K
Feb 28, 2024Sharon MatesChairman, President & CEOSale22.6K$69.79$1.6M
Feb 28, 2024Suresh K. DurgamEVP, Chief Medical OfficerSale4.1K$70.17$288.5K
Feb 28, 2024Mark NeumannEVP, Chief Commercial OfficerSale7.9K$70.13$554.5K
Feb 28, 2024Joel S MarcusDirectorSale26.3K$68.68$1.8M
Feb 5, 2024Michael HalsteadEVP and General CounselSale11.9K$66.42$787.7K
Feb 5, 2024Sharon MatesChairman, President & CEOSale33.9K$67.07$2.3M
Feb 5, 2024Mark NeumannEVP, Chief Commercial OfficerSale11.9K$67.15$796.4K
Feb 5, 2024Lawrence J. HinelineSVP of Finance, CFOSale11.2K$66.62$745.0K
Feb 5, 2024Suresh K. DurgamEVP, Chief Medical OfficerSale6.2K$67.19$414.4K

Showing the 25 most recent of 139 Form 4 filings for Intra-Cellular Therapies, Inc..

Most active ITCI insiders

  • Sharon Mates27 filings
  • Lawrence J. Hineline23 filings
  • Michael Halstead21 filings
  • Mark Neumann20 filings
  • Suresh K. Durgam15 filings

Ask anything about ITCI insider activity

Use Trabud's AI agent to query Intra-Cellular Therapies, Inc.'s Form 4 history in plain English — "Show me ITCI CEO purchases this year" or compare it against any other ticker.

Open the AI agent

ITCI insider trading FAQ

Are Intra-Cellular Therapies, Inc. insiders buying or selling?

Across 139 SEC Form 4 filings, Intra-Cellular Therapies, Inc. (ITCI) insiders reported 7 open-market purchases totaling $11.5M and 132 sales totaling $200.6M. That is a net selling position of $189.1M.

How many insiders trade ITCI stock?

13 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Intra-Cellular Therapies, Inc.. The most recent filing was accepted on Dec 6, 2024.

Where does Trabud get ITCI insider trading data?

All ITCI insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.

Looking for another company? Browse all tracked companies.

Related Content